Jeffrey Jacobson, MD
Co-Director, Center for Translational AIDS Research
- Contact Information
- About Me
Dr. Jeffrey M. Jacobson has extensive experience in the care and investigative study of patients with HIV, hepatitis B, and hepatitis C infection. His particular focus of research has been on the immunology and immunopathogenesis of HIV infection, including vaccine and other immune- and gene-based therapies. Recently, he has been studying long-acting parenteral antibody and other therapies against HIV infection. He has chaired numerous clinical research studies involving pathogenesis, pharmacokinetics, and treatment in and outside the NIH-sponsored AIDS Clinical Trials Group (ACTG). In addition, he has chaired several ACTG committees, including the Immunology Committee and the Translational Research and Drug Development Committee, and has been a member of the Scientific Agenda Steering Committee of the ACTG. He has co-chaired the Long Acting Drug Task Force in the ACTG, and currently serves as chair of the Microbiome Focus Group and co-chair of the Therapeutic Vaccination Focus Group.
- Education, Training & Credentials
- Fellowship, Infectious Diseases, Mount Sinai Medical Center, New York, NY, 1982
- Residency, Internal Medicine, Mount Sinai Medical Center, New York, NY, 1980
- Internship, Internal Medicine, University of Wisconsin Hospitals, Madison, WI, 1978
- MD, Cornell University Medical College, New York, NY, 1977
- BA, Biology, Cornell University, Ithaca, NY, 1973
- Internal Medicine
- Sub-specialty of Infectious Diseases
- American Society for Microbiology
- Fellow, Infectious Diseases Society of America
- International AIDS Society
Jacobson, J. M., Colman, N., Ostrow, N., Simson, R. W., Tomesch, D., Marlin, L., Rao, M. E., Mill, J., Clemens, J., and A. M. Prince. Passive immunotherapy in the treatment of advanced HIV infection. Journal of Infectious Diseases, 168: 298-305, 1993.
Jacobson, J. M., Davidian, M., Rainey, R., et al. Pyrimethamine pharmacokinetics in HIV- infected patients seropositive for Toxoplasma gondii. Antimicrobial Agents and Chemotherapy, 40: 1360-1365, 1996.
Jacobson, J. M., Greenspan, J. S., Spritzler, J., et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. New England Journal of Medicine, 336: 1487-93, 1997.
Jacobson, J. M., Spritzler, J., Fox, L., et al., and the NIAID AIDS Clinical Trials Group. Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. Journal of Infectious Diseases, 180: 61-67, 1999.
Jacobson, J. M., Lowy, I., Fletcher, C. V., et al. Single-dose safety, pharmacology and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. Journal of Infectious Diseases, 182: 326-329, 2000.
Jacobson JM, Feinman L, Liebus L, Ostrow N, Koslowski V, Tobia A, Cabana BE, Lee D, Spritzler J, Prince AM. Pharmacokinetics, safety, and antiviral effects of hypericin, a derivative of St. Johns wort plant, in patients with chronic hepatitis C virus infection. Antimicrob Agents Chemother. 2001;45:517-24.
Jacobson, J. M., Hafner, R., Holden-Wiltze, J., Luft, B. J., and the NIAID AIDS Clinical Trials Group. A dose-escalation, phase I/II study of oral azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in patients with AIDS. AIDS, 15: 583-589, 2001.
Jacobson, J. M., Greenspan, J. S., Spritzler, J., et al., and the NIAID AIDS Clinical Trials Group. Thalidomide in low intermittent doses does not prevent HIV-associated aphthous ulcer recurrence. Journal of Infectious Diseases, 183: 343-346, 2001.
Jacobson. J. M., Lederman, M. M., Spritzler, J., et al. and the NIAID AIDS Clinical Trials Group. Granulocyte-macrophage colony stimulating factor induces modest increases in plasma HIV-RNA and CD4 lymphocyte counts in patients with uncontrolled HIV infection. Journal of Infectious Diseases, 188: 1804-1814, 2003.
Kuritzkes, D. R., Jacobson, J. M., Powderly, W. G., et al. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with human immunodeficiency virus type 1. Journal of Infectious Diseases, 189: 286-291, 2004.
Jacobson, J. M., Israel, R. J., Lowy, I., Ostrow, N. A., et al. Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrobial Agents and Chemotherapy, 48: 423-429, 2004.
Jacobson, J. M., Bucy, R. P., Spritzler, J., et al. Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068. Journal of Infectious Diseases, 194: 623-32, 2006.
Jacobson, J. M., Saag, M. S., Thompson, M. A., et al. Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. Journal of Infectious Diseases, 198: 1345-52, 2008.
Jacobson, J. M., Kuritzkes, D. R., Godofsky, E., et al. Safety, Pharmacokinetics, and Antiretroviral Activity of Multiple Doses of Ibalizumab (formerly TNX-355), an Anti-CD4 Monoclonal Antibody, in HIV-1 Infected Adults. Antimicrobial Agents and Chemotherapy, 53: 450-457, 2009. PMC2630626.
Gandhi, R. T., O’Neill, D., Bosch, R. J., …, and J. M. Jacobson. A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. Vaccine, 27: 6088-94, 2009. PMCID: PMC2820102
Jacobson J.M., Thompson M.T., Lalezari J.P., Saag, M.S., Zingman B.S., D’Ambrosio P., Stambler N., Rotshteyn Y., Marozsan A.J., Maddon P.J., Morris S.A., and W.C. Olson. Anti-HIV activity of weekly or bi-weekly treatment with subcutaneous PRO140, a CCR5 monoclonal antibody. J Infect Dis, 201: 1481-7, 2010. PMCID: PMC2856743
Jacobson JM, Wang H, Bordi R, Zheng L, Gross BH, Landay AL, Spritzler J, Routy J-R, Benson C, Aberg J, Tebas P, Haas DW, Tiu J, Coughlin K, Purdue L, Sekaly R-P; AIDS Clinical Trials Group (ACTG) A5212 Protocol Team. A randomized controlled trial of palifermin (recombinant human keratinocyte growth hormone) for the treatment of inadequate CD4+ T-lymphocyte recovery in patients with HIV-1 infection on antiretroviral therapy. J Acquir Immune Defic Syndr. 2014;66:399-406.
Jacobson, J. M., Zheng, L., Tebas, P., Wilson, C. C., Matining, R., Landay, A. L., Tiu, J., Martinez, A, Janik, J., Egan, M., Eldridge, J., Hural, J., McElrath, J., and N. Frahm. AIDS Clinical Trials Group A5281 Protocol Team. The safety and immunogenicity of an interleukin-12 enhanced multi-antigen DNA vaccine delivered intramuscularly followed by electroporation for the treatment of HIV-1 infection. Journal of AIDS, 71: 163-71, 2016. PMCID: 26761518.
Jacobson JM, Routy JP, Welles S, DeBenedette M, Tcherepanova I, Angel JB, Asmuth D, Stein D, Baril J-G, McKellar M, Margolis DM, Trottier B, Wood K, Nicolette C. Dendritic cell immunotherapy for HIV-1 infection using autologous HIV-1 RNA: a randomized, double-blind, placebo-controlled clinical trial. J Acqui Immune Defic Syndr. 2016; May 1;72:31-8.
Jacobson JM, Bosinger S, Kang M, Belaunzaran P, Matining RM, Wilson CC, Flexner C, Clagett B, Plants J, Read S, Purdue L, Myers L, Boone L, Tebas P, Kumar P, Clifford D, Douek D, Silvestri G, Landay AL, Lederman MM, and the ACTG A5258 Protocol Team. Chloroquine modestly reduces activation and interferon signatures associated with HIV-1. AIDS Res Hum Retrovir 2016;32:636-47.